Why the study?
Does the development of de novo donor-specific antibodies after heart transplantation predict poor patient survival in recipients without pre-existing DSA?
Population
243 cardiac transplant recipients who were negative for donor-specific antibodies (DSA) prior to transplant
Comparison
Development of de novo donor-specific antibodies… vs Absence of de novo donor-specific antibodies…
Design
Cohort
Follow-up
up to 13 years
Authors
Loading...
Persistent de novo DSA after heart transplant may warrant closer monitoring; leaves open whether intervention improves survival.
Does the development of de novo donor-specific antibodies after heart transplantation predict poor patient survival in recipients without pre-existing DSA?
The development of de novo persistent donor-specific antibodies after heart transplantation is an independent predictor of poor patient survival, highlighting the need for regular post-transplant monitoring.
Smith et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: